Review of Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar— Chemaitelly 2021
This is a brief audio review. In the article Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar published, 2021 by Chemaitelly and Colleagues, The outcomes and key points are as noted: BNTB162B2 m-R-N-A COVID 19 vaccine appeared to decrease in preventive efficacy 4 weeks after the second dose, but prevention against hospitalization remained high until 6 months post vaccination. Estimated BNT162b2 effectiveness against any SARS-CoV-2 infection was negligible in the first 2 weeks after the first dose. It increased to 36.8% (95% confidence interval [CI], 33.2 to 40.2) in the third week after the first dose and reached its peak at 77.5% (95% CI, 76.4 to 78.6) in the first month after the second dose. Effectiveness declined gradually thereafter, with the decline accelerating after the fourth month to reach approximately 20% in months 5 through 7 after the second dose. Effectiveness against symptomatic infection was higher than effectiveness against asymptomatic infection but waned similarly. Variant-specific effectiveness waned in the same pattern. Effectiveness against any severe, critical, or fatal case of Covid-19 increased rapidly to 66.1% (95% CI, 56.8 to 73.5) by the third week after the first dose and reached 96% or higher in the first 2 months after the second dose; effectiveness persisted at approximately this level for 6 months. In a Case–control study (with a 'test-negative' protocol') with 115,326 patients in 0-13 days after first dose; 113,380 patients in 14 days after first dose and no second dose; 115,913 patients in 28 days after the second dose. The research included patient-subjects who were the resident population of Qatar, and whose information was housed in a national-federal SARS-COV-2 database.
Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar Hiam Chemaitelly, Patrick Tang, Mohammad R. Hasan, Sawsan AlMukdad, Hadi M. Yassine, Fatiha M. Benslimane, Hebah A. Al Khatib, Peter Coyle, Houssein H. Ayoub, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F. Abdul Rahim, Gheyath K. Nasrallah, Mohamed Ghaith Al Kuwari, Hamad Eid Al Romaihi, Adeel A. Butt, Mohamed H. Al-Thani, Abdullatif Al Khal, Roberto Bertollini, Laith J. Abu-Raddad medRxiv 2021.08.25.21262584; doi: https://doi.org/10.1101/2021.08.25.21262584
